Bioxyne Limited · ASX:BXN
Bioxyne — H1 FY2026 Earnings Presentation
17 slides from Bioxyne's earnings presentation, Feb 26, 2026
Slide 1: H1 FY2026 Results Presentation
H1 FY2026 Results Presentation ASX:BXN February 2026
Slide 2: Redefining Medicine
Redefining Medicine World’s Fastest Growing Pharmaceutical Manufacturer of Cannabis | Psilocybin | MDMA for patients with unmet clinical needs
Slide 3: H1 FY2026 Overview
H1 FY2026 Overview Record half driven by sustained and rising demand for GMP-manufactured medicinal cannabis, MDMA, and psilocybin products $31.3m $7.3m NPAT $20m Revenue +121% (on pcp) $7.6m Net Assets +149% (on pcp) $8.3M Adj. EBITDA Cash on hand +$8m (on pcp) Major milestone Entry into UK, German
Slide 4: H1 FY26 Financial Results
H1 FY26 Financial Results REVENUE GUIDANCE ($M) Revenue Record revenue: A$31.3M (+149% vs. PCP) $43.9m driven by: $33.9m • Increasing demand for GMP-manufactured cannabis, MDMA and psilocybin medicinal products $31.1m $31.1m $31.1m • Demonstrated ability to scale manufacturing and $4.7m $4.7m $12.6m
Slide 5: Profit & Loss
Profit & Loss H1 FY26 H1 FY25 Commentary Revenue from customers 31,310 12,563 Other income 70 3 Changes in inventories of finished goods and work in progress 583 626 Reflects increase in revenue and additional costs of H1 FY2025 Raw materials and consumables used (13,565) (3,709) adjusted in H2 FY20
Slide 6: Balance Sheet
Balance Sheet ASSETS Dec-25 Jun-25 Commentary Current Assets Cash and cash equivalents $7.6m $7.7m • Receivables +142% Trade receivables $5.8m $2.4m Current tax receivables $0.1m $1.2m • Other Current Assets = Prepayments to suppliers for product Other current assets $3.4m $0.9m Inventories $11.7m $
Slide 7: Cash receipts and inventory
Cash receipts and inventory CASH RECEIPTS & NET CASH USED IN OPERATING ACTIVITIES $17.2m $12.9m $10.7m $6.8m $7.4m $8.5m Commentary $1.8m $1.7m $1.6m $2.5m $1.2m • Operating cash outflow of $1.6m (Q2 +$2.5m) due to strategic investment inventory, which increased to $11.7m as of 31 Dec 25 (from $3.6m
Slide 8: Australian Strategy
wee a .. Australian Stra SOs 4 2 oo aes | ee =
Slide 9: Australian Growth Strategy
Australian Growth Strategy Australian Medical Cannabis Market Explosive Growth Underpins Domestic Leadership AUSTRALIAN MARKET GROWTH CATALYSTS AUSTRALIAN MEDICINAL CANNABIS PRESCRIPTIONS1 1740k 1304k Capacity Expansion Procurement & White-Label 4 new clean rooms operational Significant inventory 96
Slide 10: Vision & Strategy
Vision & Strategy Multinational Pharmaceutical Manufacturer Manufacturing Dominance • To become a market leading manufacturer in key markets and product categories • Focusing on white label manufacturing for medicine brands, wholesalers, clinics supplying patients • To be fully licensed (Manufacturi
Slide 11: Australian Manufacturing Capacity
Australian Manufacturing Capacity >889 ~8.2 million >240,000 Units $250m Product SKU variants Finished Medicine Finished products delivered Total Estimated manufactured by BLS Products per year per month (Q2 avg) Revenue Capacity / year Finished Product Inhalable (liquid) / Oral Solution MDMA + Psil
Slide 12: International Strategy
ef 4 International St Poul 4 2 oo aes | ee =
Slide 13: Controlling Local Market Access & Supply
Controlling Local Market Access & Supply Germany & Europe • Germany is key to European success • Czechia plans ready, on hold as Bioxyne assesses alternative opportunity • Initial shipments to distribution partner Adrex Pharma GmbH generated A$2.7 million in H1 FY26 revenue • Regulatory developments
Slide 14: A$3.5bn+ 2026 TAM and Growing
A$3.5bn+ 2026 TAM and Growing (Medicinal Cannabis Only) Germany UK EU excl. Germany Australia Est. No. Monthly Recurring Patients 350,000 80,000 100,000 250,000 Est. Avg. Spend/ patient/year $4,285 $6,250 $5,000 $4,000 Est. Market Size A$/year $1.5 Billion $0.5 Billion $0.5 Billion $1 Billion Est. M
Slide 15: A Compelling Opportunity
A Compelling Opportunity Increasing Market Share in Continue scaling UK and Germany UK GMP Licensed Manufacturing Australia distribution Site EU GMP Licensed Manufacturing New manufacturing contracts Building customer base and Plan to own and operate company- Site Plans and driving growth of white l
Slide 16: Corporate Structure
Corporate Structure CAPITAL STRUCTURE FY26 GUIDANCE Share price $0.052 Revenue $65m to $75m Market capitalisation $116.5m EBITDA $16.5m - $19m 52-week high $0.060 52-week low $0.019 Directors BXN Share Price Performance – 12 Months (Jul 2024 – Feb 2026) Other $0.06 60m 31% Top 20 $0.04 40m 69% Other
Slide 17: H1 FY2026 Results Presentation
H1 FY2026 Results Presentation ASX:BXN February 2026